Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3989248 | Journal of Thoracic Oncology | 2015 | 7 Pages |
Abstract
A concurrent PIK3CA mutation is a poor prognostic factor in patients with advanced EGFR-mutant or KRAS-mutant lung adenocarcinomas. There was no evidence that clinical benefit from EGFR TKI monotherapy is affected by a concurrent PIK3CA mutation in EGFR-mutant lung cancers.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Juliana MD, Kaitlin M. MS, Camelia S. MD, MS, Andrew MD, Matthew D. MD, Jamie E. MD, Mark G. MD, Maria E. MD, Marc MD, Alexander MD,